OpGen (OPGN) Stock Forecast, Price Target & Predictions
OPGN Stock Forecast
OpGen stock forecast is as follows: an average price target of $0.67 (represents a -61.71% downside from OPGN’s last price of $1.75) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
OPGN Price Target
OPGN Analyst Ratings
OpGen Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jul 11, 2022 | Ben Haynor | Industrial Alliance Securities | $0.67 | $0.61 | 9.25% | -61.71% |
OpGen Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $1.75 | $1.75 | $1.75 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Jul 11, 2022 | Alliance Global Partners | - | Buy | Downgrade |
OpGen Financial Forecast
OpGen Revenue Forecast
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Jun 16 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | $699.02K | - | $913.44K | $721.63K | $448.71K | $967.21K | $469.75K | $1.43M | $1.24M | $811.62K | $829.72K | $1.35M | $1.06M | $1.19M | $616.93K | $820.67K | $648.22K | $1.01M | $1.02M | $846.23K | $771.77K | $1.18M |
Avg Forecast | $2.10M | $1.80M | $1.50M | $1.20M | $1.00M | $900.00K | $900.00K | $1.60M | $600.00K | $400.00K | $1.00M | $1.05M | $1.40M | $1.10M | $1.13M | $1.33M | $1.30M | $1.00M | $1.20M | $600.00K | $900.00K | $900.00K | $1.02M | $1.11M | $952.00K | $607.89K | $892.97K |
High Forecast | $2.10M | $1.80M | $1.50M | $1.20M | $1.00M | $900.00K | $900.00K | $1.60M | $600.00K | $400.00K | $1.00M | $1.05M | $1.40M | $1.10M | $1.13M | $1.33M | $1.30M | $1.00M | $1.20M | $600.00K | $900.00K | $900.00K | $1.02M | $1.11M | $1.14M | $729.47K | $1.07M |
Low Forecast | $2.10M | $1.80M | $1.50M | $1.20M | $1.00M | $900.00K | $900.00K | $1.60M | $600.00K | $400.00K | $1.00M | $1.05M | $1.40M | $1.10M | $1.13M | $1.33M | $1.30M | $1.00M | $1.20M | $600.00K | $900.00K | $900.00K | $1.02M | $1.11M | $761.60K | $486.31K | $714.38K |
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 15 | 9 | 9 | 16 | 8 | 10 | 16 | 18 | 7 | 8 |
Surprise % | - | - | - | - | - | 0.78% | - | 0.57% | 1.20% | 1.12% | 0.97% | 0.45% | 1.02% | 1.13% | 0.72% | 0.62% | 1.04% | 1.06% | 0.99% | 1.03% | 0.91% | 0.72% | 0.99% | 0.92% | 0.89% | 1.27% | 1.32% |
OpGen EBITDA Forecast
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Jun 16 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 15 | 9 | 9 | 16 | 8 | 10 | 16 | 18 | 7 | 8 |
EBITDA | - | - | - | - | - | $-3.19M | - | $-4.69M | $-4.54M | $-6.20M | $-5.26M | $-5.33M | $-5.18M | $-4.02M | $-5.15M | $-13.14M | $-5.13M | $-5.78M | $-5.74M | $-3.68M | $-2.24M | $-3.20M | $-2.33M | $-3.57M | $-2.84M | $-4.79M | $-4.86M |
Avg Forecast | $-2.10M | $-1.80M | $-1.50M | $-14.86M | $-1.00M | $-900.00K | $-900.00K | $-13.51M | $-4.22M | $-400.00K | $-1.00M | $-12.28M | $-1.40M | $-1.10M | $-1.13M | $-13.14M | $-1.30M | $-1.00M | $-1.20M | $-2.36M | $-900.00K | $-900.00K | $-1.02M | $-2.37M | $-3.14M | $-3.51M | $-3.30M |
High Forecast | $-2.10M | $-1.80M | $-1.50M | $-11.89M | $-1.00M | $-900.00K | $-900.00K | $-10.81M | $-3.38M | $-400.00K | $-1.00M | $-9.83M | $-1.40M | $-1.10M | $-1.13M | $-10.51M | $-1.30M | $-1.00M | $-1.20M | $-1.89M | $-900.00K | $-900.00K | $-1.02M | $-1.89M | $-2.51M | $-2.81M | $-2.64M |
Low Forecast | $-2.10M | $-1.80M | $-1.50M | $-17.84M | $-1.00M | $-900.00K | $-900.00K | $-16.22M | $-5.07M | $-400.00K | $-1.00M | $-14.74M | $-1.40M | $-1.10M | $-1.13M | $-15.77M | $-1.30M | $-1.00M | $-1.20M | $-2.83M | $-900.00K | $-900.00K | $-1.02M | $-2.84M | $-3.77M | $-4.21M | $-3.96M |
Surprise % | - | - | - | - | - | 3.55% | - | 0.35% | 1.08% | 15.49% | 5.26% | 0.43% | 3.70% | 3.65% | 4.57% | 1.00% | 3.95% | 5.78% | 4.78% | 1.56% | 2.49% | 3.55% | 2.29% | 1.51% | 0.90% | 1.36% | 1.47% |
OpGen Net Income Forecast
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Jun 16 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 15 | 9 | 9 | 16 | 8 | 10 | 16 | 18 | 7 | 8 |
Net Income | - | - | - | - | - | $-4.06M | - | $-7.02M | $-9.97M | $-14.69M | $-6.41M | $-7.76M | $-6.81M | $-6.06M | $-7.09M | $-14.85M | $-7.11M | $-7.68M | $-7.48M | $-3.95M | $-2.52M | $-3.48M | $-2.59M | $-3.85M | $-3.05M | $-4.98M | $-5.05M |
Avg Forecast | $-1.88M | $-2.14M | $-2.28M | $-16.80M | $-3.35M | $-5.76M | $-9.52M | $-15.27M | $-4.56M | $-32.17M | $-40.21M | $-13.89M | $-41.55M | $-50.93M | $-52.27M | $-14.85M | $-83.10M | $-96.50M | $-136.71M | $-2.53M | $-217.13M | $-1.04B | $-911.39M | $-2.55M | $-3.37M | $-3.65M | $-3.43M |
High Forecast | $-1.88M | $-2.14M | $-2.28M | $-13.44M | $-3.35M | $-5.76M | $-9.52M | $-12.22M | $-3.65M | $-32.17M | $-40.21M | $-11.11M | $-41.55M | $-50.93M | $-52.27M | $-11.88M | $-83.10M | $-96.50M | $-136.71M | $-2.03M | $-217.13M | $-1.04B | $-911.39M | $-2.04M | $-2.70M | $-2.92M | $-2.74M |
Low Forecast | $-1.88M | $-2.14M | $-2.28M | $-20.16M | $-3.35M | $-5.76M | $-9.52M | $-18.33M | $-5.47M | $-32.17M | $-40.21M | $-16.66M | $-41.55M | $-50.93M | $-52.27M | $-17.82M | $-83.10M | $-96.50M | $-136.71M | $-3.04M | $-217.13M | $-1.04B | $-911.39M | $-3.06M | $-4.05M | $-4.38M | $-4.11M |
Surprise % | - | - | - | - | - | 0.70% | - | 0.46% | 2.19% | 0.46% | 0.16% | 0.56% | 0.16% | 0.12% | 0.14% | 1.00% | 0.09% | 0.08% | 0.05% | 1.56% | 0.01% | 0.00% | 0.00% | 1.51% | 0.90% | 1.36% | 1.47% |
OpGen SG&A Forecast
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Jun 16 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 15 | 9 | 9 | 16 | 8 | 10 | 16 | 18 | 7 | 8 |
SG&A | - | - | - | - | - | $2.37M | - | $3.45M | $3.20M | $3.05M | $3.30M | $3.68M | $3.50M | $3.09M | $3.49M | $3.56M | $3.09M | $3.29M | $3.54M | $1.98M | $1.67M | $1.94M | $1.99M | $2.12M | $2.12M | $3.07M | $3.37M |
Avg Forecast | $6.91M | $5.92M | $4.94M | $3.95M | $3.29M | $2.96M | $2.96M | $5.26M | $1.97M | $1.32M | $3.29M | $3.45M | $4.61M | $3.62M | $3.70M | $4.38M | $4.28M | $3.29M | $3.95M | $1.97M | $2.96M | $2.96M | $3.34M | $3.65M | $3.13M | $2.00M | $2.94M |
High Forecast | $6.91M | $5.92M | $4.94M | $3.95M | $3.29M | $2.96M | $2.96M | $5.26M | $1.97M | $1.32M | $3.29M | $3.45M | $4.61M | $3.62M | $3.70M | $4.38M | $4.28M | $3.29M | $3.95M | $1.97M | $2.96M | $2.96M | $3.34M | $3.65M | $3.76M | $2.40M | $3.53M |
Low Forecast | $6.91M | $5.92M | $4.94M | $3.95M | $3.29M | $2.96M | $2.96M | $5.26M | $1.97M | $1.32M | $3.29M | $3.45M | $4.61M | $3.62M | $3.70M | $4.38M | $4.28M | $3.29M | $3.95M | $1.97M | $2.96M | $2.96M | $3.34M | $3.65M | $2.51M | $1.60M | $2.35M |
Surprise % | - | - | - | - | - | 0.80% | - | 0.66% | 1.62% | 2.32% | 1.00% | 1.06% | 0.76% | 0.85% | 0.94% | 0.81% | 0.72% | 1.00% | 0.90% | 1.00% | 0.57% | 0.65% | 0.59% | 0.58% | 0.68% | 1.54% | 1.15% |
OpGen EPS Forecast
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Jun 16 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 15 | 9 | 9 | 16 | 8 | 10 | 16 | 18 | 7 | 8 |
EPS | - | - | - | - | - | $-0.46 | - | $-1.53 | $-4.08 | $-6.17 | $-2.75 | $-3.34 | $-3.37 | $-0.16 | $-0.19 | $-0.50 | $-0.34 | $-0.40 | $-0.49 | $-0.53 | $-0.61 | $-3.95 | $-3.00 | $-8.20 | $-15.00 | $-95.00 | $-190.00 |
Avg Forecast | $-1.40 | $-1.60 | $-1.70 | $-1.90 | $-2.50 | $-4.30 | $-7.10 | $-12.00 | $-20.00 | $-24.00 | $-30.00 | $-32.00 | $-31.00 | $-38.00 | $-39.00 | $-48.00 | $-62.00 | $-72.00 | $-102.00 | $-78.00 | $-162.00 | $-778.00 | $-680.00 | $-1.23K | $-18.60 | $-2.75 | $-4.75 |
High Forecast | $-1.40 | $-1.60 | $-1.70 | $-1.90 | $-2.50 | $-4.30 | $-7.10 | $-12.00 | $-20.00 | $-24.00 | $-30.00 | $-32.00 | $-31.00 | $-38.00 | $-39.00 | $-48.00 | $-62.00 | $-72.00 | $-102.00 | $-78.00 | $-162.00 | $-778.00 | $-680.00 | $-1.23K | $-14.88 | $-2.20 | $-3.80 |
Low Forecast | $-1.40 | $-1.60 | $-1.70 | $-1.90 | $-2.50 | $-4.30 | $-7.10 | $-12.00 | $-20.00 | $-24.00 | $-30.00 | $-32.00 | $-31.00 | $-38.00 | $-39.00 | $-48.00 | $-62.00 | $-72.00 | $-102.00 | $-78.00 | $-162.00 | $-778.00 | $-680.00 | $-1.23K | $-22.32 | $-3.30 | $-5.70 |
Surprise % | - | - | - | - | - | 0.11% | - | 0.13% | 0.20% | 0.26% | 0.09% | 0.10% | 0.11% | 0.00% | 0.00% | 0.01% | 0.01% | 0.01% | 0.00% | 0.01% | 0.00% | 0.01% | 0.00% | 0.01% | 0.81% | 34.55% | 40.00% |
OpGen Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
BJDX | Bluejay Diagnostics | $0.07 | $10.00 | 14185.71% | Buy |
VAPO | Vapotherm | $2.17 | $128.00 | 5798.62% | Hold |
SGHT | Sight Sciences | $4.66 | $10.25 | 119.96% | Hold |
NPCE | NeuroPace | $6.37 | $12.88 | 102.20% | Buy |
HSCS | Heart Test Laboratories | $2.73 | $3.00 | 9.89% | Buy |
OPGN | OpGen | $1.75 | $0.67 | -61.71% | Buy |
OPGN Forecast FAQ
Is OpGen a good buy?
Yes, according to 1 Wall Street analysts, OpGen (OPGN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of OPGN's total ratings.
What is OPGN's price target?
OpGen (OPGN) average price target is $0.67 with a range of $0.67 to $0.67, implying a -61.71% from its last price of $1.75. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will OpGen stock go up soon?
According to Wall Street analysts' prediction for OPGN stock, the company can go down by -61.71% (from the last price of $1.75 to the average price target of $0.67), down by -61.71% based on the highest stock price target, and down by -61.71% based on the lowest stock price target.
Can OpGen stock reach $3?
OPGN's average twelve months analyst stock price target of $0.67 does not support the claim that OpGen can reach $3 in the near future.
What are OpGen's analysts' financial forecasts?
OpGen's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $4.4M (high $4.4M, low $4.4M), average EBITDA is $-16.313M (high $-13.611M, low $-19.016M), average net income is $-33.904M (high $-30.849M, low $-36.959M), average SG&A $14.48M (high $14.48M, low $14.48M), and average EPS is $-25.9 (high $-25.9, low $-25.9). OPGN's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $6.6M (high $6.6M, low $6.6M), average EBITDA is $-20.264M (high $-17.292M, low $-23.237M), average net income is $-23.101M (high $-19.74M, low $-26.461M), average SG&A $21.71M (high $21.71M, low $21.71M), and average EPS is $-6.6 (high $-6.6, low $-6.6).
Did the OPGN's actual financial results beat the analysts' financial forecasts?
Based on OpGen's last annual report (Dec 2022), the company's revenue was $2.61M, which missed the average analysts forecast of $3.05M by -14.51%. Apple's EBITDA was $-22.172M, beating the average prediction of $-17.909M by 23.80%. The company's net income was $-36.743M, missing the average estimation of $-90.819M by -59.54%. Apple's SG&A was $13.23M, beating the average forecast of $10.03M by 31.83%. Lastly, the company's EPS was $-15.05, missing the average prediction of $-106 by -85.80%. In terms of the last quarterly report (Sep 2023), OpGen's revenue was $699.02K, missing the average analysts' forecast of $900K by -22.33%. The company's EBITDA was $-3.192M, beating the average prediction of $-900K by 254.66%. OpGen's net income was $-4.063M, missing the average estimation of $-5.763M by -29.50%. The company's SG&A was $2.37M, missing the average forecast of $2.96M by -19.93%. Lastly, the company's EPS was $-0.46, missing the average prediction of $-4.3 by -89.30%